(NASDAQ:CBUS), Nonbinding Letter of Intent (LOI) sets framework for potential 2027 market entry in Ecuador and Colombia, followed by expansion into Peru, Central America and the Caribbean Expected to build on success under the existing 2024 material transfer agreement, shifting focus to market execution and revenue generation for co-developed herbicide-tolerant (HT) rice traits SAN DIEGO, […]

(NASDAQ:MPLT), SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The Fast

(NASDAQ:IMDX), GraftAssure(TM) technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian site GraftAssureDx(TM) FDA IVD approval application 95% complete at year-end; expect full submission in coming weeks Accelerating planned UK CE mark and EU IVDR submission to first half 2026, following successful TUV SUD ISO 13485 stage 1

(NASDAQ:GOGO), Broomfield,CO., Jan. 05, 2026 (GLOBE NEWSWIRE) — Gogo Inc. (NASDAQ: GOGO) (“Gogo,” “we,” “us” or the “Company”), issued a “report card” today regarding its 2025 year-end progress on critical new product initiatives as it transitions from being a domestic supplier of traditional Air-to-Ground (“ATG”) connectivity to becoming a global multi-orbit, ultra-high bandwidth connectivity supplier

(NASDAQ:MRKR), Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit and the expansion and persistence of Multi-Antigen Targeted T cells HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE)

(TSX-V:STUD),(Boerse Frankfurt – Freiverkehr:HM40.F),(OTC US:STLNF),(Other OTC:STLNF),(Frankfurt:FE0),(Boerse Frankfurt – Freiverkehr:B76), VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion“) (TSX-V: STUD; OTCQB: STLNF; FSE: B76) is pleased to announce the mobilization of personnel and equipment for the upcoming diamond drilling program at its Moonlite Property, located in the Athabasca

(NASDAQ:BENF), DALLAS, Jan. 05, 2026 (GLOBE NEWSWIRE) — Beneficient (the “Company”) (Nasdaq: BENF), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that, by letter dated January 2, 2026, the Company was notified by The Nasdaq Stock Market, LLC (“Nasdaq”) that

(HKSE:2665.HK), LAS VEGAS, Jan. 05, 2026 (GLOBE NEWSWIRE) — As CES 2026 opens this week, Seyond, a global leader in high-performance LiDAR solutions, invites attendees to experience live autonomous demonstrations and next-generation LiDAR technology at its booth in LVCC – West Hall, Booth #6059. Designed as an interactive, two-level experience, Seyond's CES booth highlights how

(NASDAQ:JBIO), JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis

(TSX-V:EVER),(OTC US:EVGUF),(Other OTC:EVGUF),(Frankfurt:5EG), TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Evergold Corp. (TSX-V: EVER, WKN: A2PTHZ) (“Evergold” or the “Company“) is pleased to announce a strategic non-brokered private placement (the “Financing“) with principals associated with the Ore Group, acting in their individual capacities. This investment marks the beginning of a broader repositioning of Evergold, including